- Home
- LTRN vs ITRM Comparison
LTRN vs ITRM Comparison
Compare LTRN & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- ITRM
- Stock Information
- Founded
- LTRN 2013
- ITRM 2015
- Country
- LTRN United States
- ITRM Ireland
- Employees
- LTRN N/A
- ITRM N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- ITRM Health Care
- Exchange
- LTRN Nasdaq
- ITRM Nasdaq
- Market Cap
- LTRN 36.0M
- ITRM 40.0M
- IPO Year
- LTRN 2020
- ITRM 2018
- Fundamental
- Price
- LTRN $3.89
- ITRM $0.76
- Analyst Decision
- LTRN Strong Buy
- ITRM Strong Buy
- Analyst Count
- LTRN 1
- ITRM 2
- Target Price
- LTRN $25.00
- ITRM $7.00
- AVG Volume (30 Days)
- LTRN 542.7K
- ITRM 787.8K
- Earning Date
- LTRN 08-07-2025
- ITRM 08-05-2025
- Dividend Yield
- LTRN N/A
- ITRM N/A
- EPS Growth
- LTRN N/A
- ITRM N/A
- EPS
- LTRN N/A
- ITRM N/A
- Revenue
- LTRN N/A
- ITRM N/A
- Revenue This Year
- LTRN N/A
- ITRM N/A
- Revenue Next Year
- LTRN N/A
- ITRM $270.19
- P/E Ratio
- LTRN N/A
- ITRM N/A
- Revenue Growth
- LTRN N/A
- ITRM N/A
- 52 Week Low
- LTRN $2.55
- ITRM $0.74
- 52 Week High
- LTRN $6.12
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- LTRN 53.98
- ITRM 27.57
- Support Level
- LTRN $3.73
- ITRM $0.81
- Resistance Level
- LTRN $4.43
- ITRM $0.90
- Average True Range (ATR)
- LTRN 0.45
- ITRM 0.08
- MACD
- LTRN -0.01
- ITRM -0.02
- Stochastic Oscillator
- LTRN 55.64
- ITRM 3.02
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.